Xolair

Prescription Biologic (Anti-IgE)

Omalizumab Injection

Manufacturer: Novartis

Description

Xolair is Novartis' omalizumab — a humanised monoclonal antibody that binds free IgE, preventing its interaction with mast cells and basophils. Approved for chronic spontaneous urticaria (CSU) refractory to antihistamines. Provides dramatic relief of hives and angioedema.

Active Compounds

No tracked compounds

Indications

  • Chronic spontaneous urticaria (refractory to H1 antihistamines)
  • Allergic asthma

Dosage

150mg or 300mg subcutaneous injection every 4 weeks. Dose not based on IgE levels for CSU.

Formulations

Prefilled syringe

Full Ingredient List

  • Omalizumab
  • L-Histidine Hydrochloride
  • L-Histidine
  • Sucrose
  • Polysorbate 20
  • Water for Injection

Side Effects

  • Injection site reactions
  • Headache
  • Arthralgia
  • Anaphylaxis (rare but monitor for 30 min post-injection)
  • Upper respiratory infections

Warnings

  • Observe patient for 30 minutes after injection (anaphylaxis risk)
  • Carry epinephrine auto-injector
  • Do not abruptly stop systemic steroids
  • Very expensive — may limit access in India
  • Not for acute urticaria